Blog Profile / Pharmalot

Filed Under:Medical / Pharmaceutical
Posts on Regator:3648
Posts / Week:7.5
Archived Since:November 10, 2008

Blog Post Archive

Pharmalot… PharmaWhat?… Until We Meet Again…

After a brief, but rewarding stay here at The Wall Street Journal, we are taking our Pharmalot act to a different theater.

Former Teva Employee Blames Firing on Helping Feds With Bribery Probe

A former Teva employee claims she was fired for helping U.S. officials with their investigation into FCPA violations.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Glaxo, MannKind and Lots More!!

Good morning, everyone, and how are you today? The heat continues to rise higher here on the Pharmalot campus, where we are hoping for storm clouds to wash away the humidity that has so far characterized the past few days. One can dream,...Show More Summary

Another California County Wants Pharma to Pay for Drug Take-Backs

Yet another California county plans to ask the pharmaceutical industry to fund a drug take-back program.

Serious Risks About Existing Drugs Aren’t Given to Trial Participants

New research finds some serious risks are not disclosed on consent forms given to trial participants for studies involving approved drugs.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on NantKwest, Biogen and Lots More!!

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Show More Summary

We Need a Vaccine Development Fund for ‘Death Valley:’ Mahmoud Explains

Former Merck vaccine head Adel Mahmoud explains the reasoning for creating a global vaccine development fund.

Has Mylan Labs Been Stichting it to Shareholders? A Lawsuit Says ‘Yes!’

Some Mylan shareholders claim in a lawsuit that a tax inversion the drug maker pursued to thwart hostile takeovers was predicated on a “sham” and that Mylan executives breached their fiduciary duty.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Merck, Regeneron and Lots More!!

Top of the morning to you. And a steamy one, it is. In fact, there is more steam rising from the grounds of the Pharmalot campus than from our ritual cup of stimulation. But this is to be expected at this time of year, yes? In any event, there is work to be done, so as always, we have assembled a few items of interest for you. Show More Summary

European Union Bans Hundreds of Drugs Over Clinical Trial Studies

The European Union has accepted a recommendation to suspend hundreds of drugs that were authorized for use based on what regulators called “flawed” studies conducted by GVK Biosciences, a clinical research organization based in Hyderabad, India.

UK May Require Doctors to Report Their Financial Ties to Drug Makers

U.K. doctors and public health officials may be required to report any financial ties to drug makers under plans that are being considered by U.K. government officials.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Teva, Allergan and Lots More!!

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because yet another busy few days await. After all, given the crush of recent developments, one could hardly say we are in the midst of summer doldrums, yes? So time to get on with it. Show More Summary

Docs are Excited About Prescribing Those New Cholesterol Drugs: Survey

A survey finds cardiologists are excited by a pair of forthcoming cholesterol-lowering meds that are expected to be effective, but expensive.

Pharmalot.. Pharmalittle.. As the Weekend Nears: We’re Catching up on Regeneron, Glaxo and Lots More!!

And so, yet another working week will soon draw to a close. You knew this would happen, yes? As you know, this is our treasured signal to daydream about weekend plans. As is often the case, we have a rather modest agenda. We hope to catch up on paperwork and reading, indulge the short people and take a nap or three. Show More Summary

U.S. Could Save up to $16B if Medicare Part D Prices are Negotiated: Paper

A new paper argues that the federal government could save between $15.2 billion and $16 billion annually if it negotiated with drug makers for Medicare Part D medicines and obtained the same prices that are paid by Medicaid or the Veterans Benefits Administration.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Drug Prices, Teva and Lots More!!

Good morning, everyone, and how are you today? We are just fine, thank you. Our spirits are lifted higher than usual today thanks to a sparkling sun and cool breezes enveloping the quieter-than-usual Pharmalot campus. This makes for a fine day to catch up on our to-do list - we hope - and forage for interesting items. Show More Summary

Funds Join Campaign to Pressure Pharma to Disclose Trial Data

A group of 85 asset managers and pension funds is teaming with a U.K. non-profit campaign to pressure drug makers to disclose clinical trial data.

Biogen Alzheimer’s Data Prompts Mixed Reactions: What the Wags Say

After months of anticipation, Biogen this morning released early-stage study data for its experimental Alzheimer’s drug and the results were mixed - as were analyst reactions.

Are Boastful Claims in Drug Ads Seen as Proxies for Effectiveness?

The FDA plans to run a pair of studies to determine the extent to which consumers view claims about a drug being the number one medicine prescribed by physicians as positie nformation or as a substitute for effectiveness data.

Pharmalot.. Pharmalittle.. Good Morning: We’re Catching up on Biogen, Lilly and Lots More!!

Hello, everyone, and how are you today? A bright shiny sun and cool breezes are enveloping the Pharmalot campus, a decidedly welcome greeting from the steamy heat of the past few days. This calls for celebration. So please join us as we reach for the mandatory cup of stimulation. Show More Summary

Copyright © 2015 Regator, LLC